---
title: Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation
nct_id: NCT03796507
overall_status: WITHDRAWN
phase: EARLY_PHASE1
sponsor: University of Rochester
study_type: INTERVENTIONAL
primary_condition: Glioma of Brain
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03796507.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03796507"
ct_last_update_post_date: 2021-04-09
last_seen_at: "2026-05-12T07:19:59.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation

**Official Title:** Early Post-surgical Temozolomide Therapy in Patients With High-Grade Gliomas Admitted to Acute Rehabilitation: A Feasibility Study

**NCT ID:** [NCT03796507](https://clinicaltrials.gov/study/NCT03796507)

## Key Facts

- **Status:** WITHDRAWN
- **Why Stopped:** Hiring freeze of research personnel due to COVID pandemic
- **Phase:** EARLY_PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 0
- **Lead Sponsor:** University of Rochester
- **Collaborators:** National Institutes of Health (NIH)
- **Conditions:** Glioma of Brain
- **Start Date:** 2021-09-01
- **Completion Date:** 2021-12-15
- **CT.gov Last Update:** 2021-04-09

## Brief Summary

The purpose of this study is to investigate the feasibility of a possible treatment regimen that could be used to delay tumor progression in patients with glioblastoma. The study is being conducted in patients who qualify for inpatient rehabilitation, as this population is particularly vulnerable to delays in initiation of chemoradiation and further tumor growth in the period between surgical resection and the start of treatment.

## Detailed Description

This is a pilot study to evaluate the feasibility and safety of early postsurgical temozolomide therapy prior to initiation of standard chemoradiation regimen in patients with glioblastoma who undergo inpatient rehabilitation. The study will be conducted with adult patients who qualify for inpatient rehabilitation following surgical resection of pathologically confirmed Grade IV glioma. Patients will begin a 21-day cycle of temozolomide starting 14 days after surgery at 75mg per square meter of body surface area daily to serve as bridge therapy. Patients will then progress to receive standard therapy following their rehabilitation stay. Patients will be assessed for their ability to complete the chemotherapy protocol without dose-limiting toxicity as well as complete inpatient rehabilitation successfully. Additionally, we will be assessing for tumor progression between the time of surgery and the time of treatment initiation.

If this study shows the expected results, the research team plans to proceed to a larger trial assessing the efficacy of early TMZ in patients with glioblastoma (GBM) who are admitted to acute inpatient rehabilitation compared to the current standard of care.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Adult patients, aged 18+
* Newly diagnosed World Health Organization (WHO) Grade IV glioma, confirmed on pathology
* Karnofsky Performance Score ≥ 60
* Subject has undergone biopsy, subtotal resection, or gross total resection of tumor
* Subject has been evaluated by physical therapy and thought to be a candidate for acute rehabilitation
* Subject must be accepted for admission on 5-1200 unit at Strong Memorial Hospital
* Subject must be able to provide informed consent
* Subject must meet the following laboratory parameters:

  * Absolute neutrophil count \> 1.5 x103/uL
  * Platelet count \> 140 x103/uL
  * Alanine transaminase \< 135 U/L
  * Aspartate transaminase \< 120 U/L

Exclusion Criteria:

* Subject has received previous treatment for high-grade glioma
* Subject has other active malignancy
* Subject is currently pregnant or breastfeeding
* Subject is a women of childbearing potential who is not using a reliable method of contraception
* Subject has history of hypersensitivity to temozolomide
```

## Arms

- **Temozolomide Arm** (EXPERIMENTAL) — This study will only include one treatment group who will receive oral temozolomide at 75 mg per square meter of body surface area daily for 21 days before progressing to standard chemoradiation treatment.

## Interventions

- **Temozolomide** (DRUG) — oral temozolomide at 75 mg per square meter of body surface area daily for 21 days

## Primary Outcomes

- **The number of patient who fail to complete temozolomide (TMZ)** _(time frame: 1 month)_ — The number of subjects who fail to complete early TMZ plus inpatient rehabilitation for any reason, including adverse events or progression or patient withdrawal

## Secondary Outcomes

- **Mean functional independence measure (FIM) score** _(time frame: 1 month)_
- **Response rate to TMZ** _(time frame: 1 month)_

## Locations (1)

- University of Rochester Medical Center, Rochester, New York, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of rochester medical center|rochester|new york|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03796507.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03796507*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*